DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Posição atual:
>
> This Story


Início de uma sessão ou Registo to rate this News Story
Forward Printable StoryPrint Comment

 

 

Oncology Homepage

FDA clears IsoRay's and GT's cesium-131 based brachytherapy Performed during surgery to remove brain tumor, reduces follow-ups

Onkos Surgical and Insight Medical partner to bring augmented reality to tumor surgery Could this become the new standard of care?

Andrew J. Evans and Erik P. Sulman NYU Langone Health hires nationally renowned radiation oncologists

Combined radionuclide therapy and immunotherapy shows promise New research unveiled at SNMMI meeting

RaySearch releases RayStation 8A Offers greater support for radiation, proton and carbon ion therapies

Radiotherapy IT company CruxQS acquires RDS Will expand footprint for FlowBoard workflow management system

New model boosts flow efficiency of particle accelerators May lead to smaller accelerators, easier to operate at reduced costs

Why are breast cancer survivors foregoing recommended screening? Study finds poor adherence to annual mammogram guidelines

Is low cost Proton-to-Carbon Heavy Ion radiotherapy coming soon? Best Particle Therapy plans to bring smaller footprint system to market in two to three years

Researchers develop AI approach for high-risk clinical tumor volumes Assisting low- and middle-income countries that lack contouring expertise

iCAD's Xoft Axxent balloon applicators

China approves iCAD Xoft Axxent balloon applicators for early-stage breast cancer treatment

por John R. Fischer , Staff Reporter
The China Food & Drug Administration (CFDA) has approved the use of iCAD’s Xoft Axxent balloon applicators for treating early-stage breast cancer.

Doctors and clinicians in China can now use the applicators, a component of the the Xoft Axxent Electronic Brachytherapy (eBx) System, to administer intraoperative radiation therapy (IORT) to the site of tumors during the lumpectomy for patients with stage one or two breast cancer as well as those with Ductal carcinoma in situ (DCIS) that has not yet progressed to the lymph nodes.

Story Continues Below Advertisement

Source-Ray, Inc. - Innovations In Portable X-Ray

SRI is a leading Developer, Manufacturer & Supplier of Innovative Portable Imaging Equipment. We offer Lightweight, Agile, Easy to Maneuver Portable X-Ray Systems ideal for maneuvering in tight spaces. Call us at 631-244-8200



“More and more women are searching for effective alternatives for the treatment of early stage breast cancer,” Daniel Arnoff, vice president of global sales at iCAD, told HCB News. “Many women cannot comply with the six to eight weeks of external beam radiation following their surgery. IORT is done at the time of surgery, allowing appropriately selected patients to complete their full course of radiation in one day.”

The Xoft System’s miniaturized x-ray source is inserted into an applicator as a channel for administering a single and exact, high-dose rate of low energy radiation treatment to the lumpectomy cavity. The applicator delivers the dose, targeting the cancer cells directly, so as to reduce exposure of healthy surrounding tissue to the radiation.

The applicators come in different sizes and shapes and can be filled with different volumes of saline to fit the contour of the cavity exactly and enable delivery of a more conformal dose of radiation. They also come in a sterile pack, eliminating the need for sterilization and decreasing the risk of cross-contamination.

Arnoff says the Xoft system and its applicators have the potential to become a standard option for treating breast cancer in China, and that with more research, could be used to treat other forms of cancer.

“As additional data emerge in support of other clinical applications, we expect that other countries, including China, will consider utilizing the Xoft System and its variety of applicators for a range of cancers,” he said.

The Xoft system and its applicators are FDA-approved and CE-marked to treat cancer in any part of the body, including early-stage breast cancer, non-melanoma skin cancer and gynecological cancers.

Oncology Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente a Sua Perceção da Marca
Leilões + Vendas Privadas
Comece
O mais melhor preço
Comprar Equipamento/Peças
Encontre
O preço o mais baixo
Notícia diária
Leia
A notícia a mais atrasada
Diretório
Browse tudo
DOTmed Usuários
Ética no DOTmed
Veja o nosso
Programa das éticas
O ouro parte o programa do vendedor
Receba PH
Pedidos
Programa do negociante do serviço do ouro
Receba RFP/PS
Pedidos
Fornecedores de Healthcare
Veja tudo
Ferramentas de HCP
Trabalhos/Treinamento
Achado/suficiência
Um trabalho
Parts Hunter +EasyPay
Comece as peças
Citações
Certificado recentemente
Vista recentemente
Usuários certificados
Recentemente Rated
Vista recentemente
Usuários certificados
Central Rental
Equipamento do aluguel
Para menos
Vender Equipamentos/Peças
Comece
A maioria de dinheiro
Preste serviços de manutenção ao Forum dos técnicos
Ajuda do achado
E conselho
Simples RFP
Comece o equipamento
Citações
Mostra de comércio virtual
Serviço do achado
Para o equipamento
O acesso e o uso deste local são sujeitos aos termos e às condições do nosso OBSERVAÇÃO LEGAL & OBSERVAÇÃO DA PRIVACIDADE
Propriedade de e proprietário DOTmeda .com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
TODOS OS DIREITOS RESERVADOS